Friday, June 22, 2012

Isis commences ISIS-APOCIIIRx Phase 2 study in hypertriglyceridemia



Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study 
evaluating ISIS-APOCIIIRx in patients with hypertriglyceridemia......


Ref:http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle_pf&ID=1509616

No comments: